Paratek's antibiotic succeeds in Phase IIb lung disease trial

By Yahoo! Finance | Nov 11, 2024 at 07:34 AM EST

Paratek Pharmaceuticals reports positive Phase IIb trial results for oral antibiotic Nuzyra in treating NTM pulmonary disease. The therapy shows improvement in symptoms with favorable trends observed. Nuzyra is also approved for other bacterial infections.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.